Please login to the form below

Not currently logged in
Email:
Password:

Accretio appoints Neil Levinson as strategy director

He joins the healthcare consultancy from Kaiser Associates

AccretioAccretio, part of the OPEN health group of companies, has appointed Neil Levinson as its strategy director.

Levinson will join the Accretio leadership team alongside managing director Richard Baderin and operations director Charlotte Richards.

Speaking of his new appointment, Levinson said: “Accretio has pioneered novel ways to support life science companies achieve improved results for their brand.

“I look forward to expanding this offering and maximising the breadth of experience from the broader OPEN Health group to provide outcomes-focused consulting and implementation services for global and UK clients.”

Most recently, Levinson was vice president at Kaiser Associates, a global strategy-consulting firm, where he led the European healthcare practice.

Prior to Kaiser, Levinson spent ten years at IMS Health, where he was senior principal, leading the UK and Ireland consulting services business.

Commenting on his appointment, Baderin, said: “Neil’s appointment cements Accretio’s evolution to a fully-fledged strategic solutions and implementation services company led by a team with pharmaceutical, consultancy and agency heritage.

“It’s great to have someone of Neil’s calibre as part of the leadership team as we embark on the next phase of Accretio’s journey.”

24th April 2018

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics